

Declaration of Incorporation of Partly Completed Machinery in compliance with Machinery Directive 2006/42/EC

for multi-turn and part-turn actuators of the following type ranges:

PROFOX PF-Q80, PF-Q150, PF-Q300, PF-Q600
PROFOX PF-M25, PF-M50, PF-M100

Manufacturer: AUMA Riester GmbH & Co KG, Aumastr. 1, 79379 Muellheim, Germany

The before mentioned multi-turn and part-turn actuators are intended for operation of industrial valves.

The following essential health and safety requirements in compliance with annex I of Directive 2006/42/EC are respected:

Articles 1.1.2, 1.1.3, 1.1.5, 1.2.1, 1.2.6, 1.3.1, 1.3.7, 1.5.1, 1.6.3, 1.7.1, 1.7.3, 1.7.4

AUMA shall be obligated to electronically submit the documents for the partly completed machinery to national authorities on request. The relevant technical documentation pertaining to the partly completed machinery described in annex VII, part B has been prepared.

Putting into service is not permitted until the final machinery into which the before mentioned multi-turn and part-turn actuators are to be incorporated has been declared in conformity with the provisions of the Directive 2006/42/EC.

Furthermore, the safety requirements of the **Low Voltage 2014/35/EU** are fulfilled by applying the following harmonised standards, as far as applicable for the products:

EN 60034-1:2010 / AC:2010
EN 61800-5-1:2007 / A1:2017

Authorised person for documentation: Michael Noll, Aumastr. 1, 79379 Muellheim, Germany

EU Declaration of Conformity

The manufacturer AUMA Riester GmbH & Co. KG declares herewith in sole responsibility, that the before mentioned devices meet the essential requirements of the following directives. The following harmonised directives were applied:

RoHS Directive 2011/65/EU

EN 50581:2012

RED Directive 2014/53/EU

EN 300 328 V2.1.1
EN 301 489-1 V2.1.1
EN 301 489-17 V3.1.1

Furthermore, the before mentioned standards of the **EMC Directive 2014/35/EU** and the following standards of the **EMC Directive 2014/30/EU** were applied:

EN 61800-3:2004 / A1:2012

Muellheim, 2020-02-01


Dr J. Hoffmann, CEO